These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19783342)

  • 1. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis.
    Deved V; Poyah P; James MT; Tonelli M; Manns BJ; Walsh M; Hemmelgarn BR;
    Am J Kidney Dis; 2009 Dec; 54(6):1089-97. PubMed ID: 19783342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis.
    Einerson B; Chaiyakunapruk N; Kitiyakara C; Maphanta S; Thamlikitkul V
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S134-46. PubMed ID: 21721439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
    Sirover WD; Siddiqui AA; Benz RL
    Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
    Brimble KS; Rabbat CG; McKenna P; Lambert K; Carlisle EJ
    J Am Soc Nephrol; 2003 Oct; 14(10):2654-61. PubMed ID: 14514745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
    Fishbane S; Berns JS
    Kidney Int; 2005 Sep; 68(3):1337-43. PubMed ID: 16105069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
    Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
    J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis.
    Clement FM; Klarenbach S; Tonelli M; Johnson JA; Manns BJ
    Arch Intern Med; 2009 Jun; 169(12):1104-12. PubMed ID: 19546410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.
    Kuragano T; Yahiro M; Kida A; Furuta M; Nagasawa Y; Hasuike Y; Nanami M; Nakanishi T
    Int J Artif Organs; 2014 Dec; 37(12):865-74. PubMed ID: 25450320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.
    Roberts TL; Obrador GT; St Peter WL; Pereira BJ; Collins AJ
    Kidney Int; 2004 Dec; 66(6):2429-36. PubMed ID: 15569336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.